COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant

1. NG J.H., BIJOL V., SPARKS M.A., SISE M.E., IZZEDINE H., JHAVERI K.D. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020; 27(5):365–76.10.1053/j.ackd.2020.09.003757472233308501Search in Google Scholar

2. VILLE S., LE BOT S., CHAPELET-DEBOUT A., BLANCHO G., FREMEAUX-BACCHI V., DELTOMBE C., et al. Atypical HUS relapse triggered by COVID-19. Kidney Int [Internet]. 2021; 99(1):267–8.10.1016/j.kint.2020.10.030765701733188793Search in Google Scholar

3. MAT O., GHISDAL L., MASSART A., AYDIN S., GOUBELLA A., BLANKOFF N., et al. Kidney Thrombotic Microangiopathy After COVID-19 Associated With C3 Gene Mutation. Kidney Int Reports. 2021;6(6):1732–7.10.1016/j.ekir.2021.03.897802869833851069Search in Google Scholar

4. KAUFELD J.K., REINHARDT M., SCHRÖDER C., BRÄSEN J.H., WIECH T., BRYLKA P., et al. Atypical HUS triggered by infection with SARS-CoV2. Kidney Int Reports. 2021; 6(10):2709-2712.10.1016/j.ekir.2021.07.004826521034258481Search in Google Scholar

5. ABDEL-WAHAB N., LOPEZ-OLIVO M.A., PINTO-PATARROYO G.P., SUAREZ-ALMAZOR M.E. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus. 2016; 25(14):1520-1531.10.1177/0961203316640912750815927060064Search in Google Scholar

6. HARZALLAH I., DEBLIQUIS A., DRÉNOU B. Frequency of lupus anticoagulant in COVID-19 patients. Journal of Thrombosis and Haemostasis. 2020; 18(10):2778.10.1111/jth.14937728364032470207Search in Google Scholar

7. DEVREESE K.M.J., LINSKENS E.A., BENOIT D., PEPERSTRAETE H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation?. J Thromb Haemost. 2020;18(9):2191–201.10.1111/jth.14994736125332619328Search in Google Scholar

8. PINETON DE CHAMBRUN M., FRERE C., MIYARA M., AMOURA Z., MARTIN-TOUTAIN I., MATHIAN A., et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?. Journal of Internal Medicine. 2021; 289(3):422-424.10.1111/joim.13126730703232529774Search in Google Scholar

9. TIWARI N.R., PHATAK S., SHARMA V.R., AGARWAL S.K. COVID-19 and thrombotic microangiopathies. Thromb Res. 2021; 202:191–198.10.1016/j.thromres.2021.04.012805592633894421Search in Google Scholar

10. YU J., YUAN X., CHEN H., CHATURVEDI S., BRAUNSTEIN E.M., BRODSKY R.A. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020; 136(18):2080–9.10.1182/blood.2020008248759684932877502Search in Google Scholar

11. NHLBI Exome Sequencing Project (ESP) Exome Variant Server [Internet]. Available from: http://evs.gs.washington.edu/EVS/Search in Google Scholar

12. CAPRIOLI J., CASTELLETTI F., BUCCHIONI S., BETTINAGLIO P., BRESIN E., PIANETTI G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003; 12(24):3385–95.10.1093/hmg/ddg36314583443Search in Google Scholar

13. NEUMANN H.P.H., SALZMANN M., BOHNERT-IWAN B., MANNUELIAN T., SKERKA C, LENK D, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet. 2003; 40(9):676–81.10.1136/jmg.40.9.676173558612960213Search in Google Scholar